The current role of warfarin
Authors:
Jana Michalcová; Alena Buliková; Jiřina Zavřelová; Marie Prudková; Miroslav Penka
Authors‘ workplace:
Oddělení klinické hematologie FN Brno, pracoviště Bohunice
Published in:
Vnitř Lék 2017; 63(12): 957-966
Category:
Reviews
Overview
Well-managed warfarin therapy remains an important method of anticoagulation in the 21st century, despite the introduction of new antithrombotics into the clinical practice. The main advantages of warfarin are decades of treatment experience, the possibility to monitor its anticoagulant effect using the INR and the last, but not least, the low cost. Currently, approximately 75 % of anticoagulated patients in the Czech Republic are treated with warfarin and warfarin remains the only option for oral anticoagulant therapy in certain clinical conditions (particularly in patients with valvular atrial fibrillation or mechanical heart valves). For physicians across specialties it is still indispensable to master the basics of safe and effective warfarin therapy, including the management of treatment complications.
Key words:
anticoagulant therapy – INR – thrombosis – warfarin
Sources
1. Van Gorp RH, Schurgers LJ. New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs). Nutrients 2015; 7(11): 9538–9557. Dostupné z DOI: <http://dx.doi.org/10.3390/nu7115479>.
2. Hirsh J, Fuster V, Ansell J et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003; 41(9): 1633–1652.
3. Státní úřad pro kontrolu léčiv. Souhrn údajů o přípravku Warfarin Orion. 2016. Dostupné z WWW: <http://www.sukl.cz/modules/medication/download.php?file=SPC99992.pdf&type=spc&as=warfarin-orion-spc>.
4. Wen MS, Lee MT. Warfarin Pharmacogenetics: New Life for an Old Drug. Acta Cardiol Sin 2013; 29(3): 235.
5. Moreau C, Loriot MA, Siguret V. Les antagonistes de la vitamine K: de leur découverte à la pharmacogénétique. Ann Biol Clin 2012; 70(5): 539–551. Dostupné z DOI: <http://dx.doi.org/10.1684/abc.2012.0740>.
6. Kessler P. Léčba orálními antikoagulancii. Orion: Praha 2000. ISBN 80–238–6017–8.
7. White HD, Gruber M, Feyzi J et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167(3): 239–245.
8. Dulíček P, Vašátková J. Zkušenosti se stanovením INR a APTT metodou POCT. Practicus 2015; 14(3): 23–25. Dostupné z WWW: http://www.quickseal.eu/img/qlabsaptt/Zkusenosti_se_stanovenim_INR_a_aPTT_metodou_POCT.pdf
9. Witt DM, Clark NP, Kaatz S et al. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis 2016; 41(1): 187–205. Dostupné z DOI: <http://dx.doi.org/10.1007/s11239–015–1319-y>.
10. Čihák R, Heinc P, Haman L et al. Fibrilace síní : doporučený diagnostický a léčebný postup České kardiologické společnosti vypracovaný Pracovní skupinou arytmie a trvalé kardiostimulace. Cor vasa 2011; 53(Suppl 1): 27–52.
11. Karetová D, Bultas J. Farmakoterapie tromboembolických stavů. 2. vyd. Maxdorf: Praha 2013. ISBN 978–80–7345–362–6.
12. Holmes MV, Hunt BJ, Shearer MJ. The role of dietary vitamin K in the management of oral vitamin K antagonists. Blood Rev 2012; 26(1): 1–14. Dostupné z DOI: <http://dx.doi.org/10.1016/j.blre.2011.07.002>.
13. Matýšková M. Warfarin, potrava a potravinové doplňky. Interní med 2010; 12(2): 87–91.
14. Kimmel SE. Warfarin pharmacogenomics: current best evidence. J Thromb Haemost 2015; 13(Suppl 1): S266-S271. Dostupné z DOI: <http://dx.doi.org/10.1111/jth.12978>.
15. Yates SG, Sarode R. New strategies for effective treatment of vitamin K antagonist-associated bleeding. J Thromb Haemost 2015; 13(Suppl 1): S180-S186. Dostupné z DOI: <http://dx.doi.org/10.1111/jth.12970>.
16. Makris M, Van Veen JJ, Tait CR et al. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 2013; 160(1): 35–46. Dostupné z DOI: <http://dx.doi.org/10.1111/bjh.12107>.
17. Gumulec J, Kessler P, Procházka V et al. Krvácivé komplikace atikoagulační léčby. Vnitř Lék 2009; 55(3): 277–289.
18. Státní úřad pro kontrolu léčiv. Souhrn údajů o přípravku Ocplex. 2015. Dostupné z WWW: <http://www.sukl.cz/modules/medication/download.php?file=SPC76551.pdf&type=spc&as=ocplex-spc>.
19. Brejcha M, Gumulec J, Penka M et al. Příprava pacientů s antikoagulační léčbou k invazivním zákrokům. Vnitř Lék 2009; 55(3): 272–275.
20. Douketis JD, Spyropoulos AC, Kaatz S et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med 2015; 373(9): 823–833. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1501035>.
21. Douketis JD, Spyropoulos AC, Spencer FA et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e326S-e350S. Dostupné z DOI: <http://dx.doi.org/10.1378/chest.11–2298>. Erratum in Chest 2012; 141(4):1129.
22. Bulik O, Buliková A, Smejkal P et al. Příprava nemocných s poruchou hemostázy ke stomatochirurgickým výkonům. Vnitř Lék 2008; 54(4): 415–420.
23. Čihák R, Haman L, Táborský M. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Summary of the document prepared by the Czech Society of Cardiology. Cor Vasa 2016; 58(6): e153-e174. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crvasa.2016.01.006>.
24. Urbánek K, Kohlová I, Ürge J et al. Informovanost, percepce rizik a compliance pacientů užívajících warfarin. Klin Farmakol Farm 2008; 22(1): 6–10. Dostupné z WWW: <https://www.klinickafarmakologie.cz/pdfs/far/2008/01/02.pdf>.
25. Steffel J, Luscher TF. Vitamin K antagonists. Ready to be replaced? Hamostaseologie 2012; 32(4): 249–257. Dostupné z DOI: <http://dx.doi.org/10.5482/ha-12050008>.
26. Kearon C, Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease. Chest 2016; 149(2): 315–352. Dostupné z DOI: <http://dx.doi.org/10.1016/j.chest.2015.11.026>.
27. Hylek EM. Dabigatran and Mechanical Heart Valves – Not as Easy as We Hoped. N Engl J Med 2013; 369(13): 1264–1266. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMe1310399>.
28. Arepally GM, Ortel TL. Changing Practice of Anticoagulation: Will Target-Specific Anticoagulants Replace Warfarin? Annu Rev Med 2015; 66: 241–253. Dostupné z DOI: <http://dx.doi.org/10.1146/annurev-med-051113–024633>.
29. Nishimura RA, Otto CM, Bonow RO et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(23): e521-e643. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0000000000000031>. Erratum in Circulation 2014; 130(13): e120. Dosage error in article text. Circulation 2014; 129(23): e651.
30. Buliková A, Smejkal P, Kissová J et al. Profylaxe a léčba antifosfolipidového syndromu – současné možnosti, úskalí a perspektivy do budoucna. Vnitř Lék 2012; 58(7–8): 110–122.
31. Arachchillage DRJ, Laffan M. Pathogenesis and management of antiphospholipid syndrome. Br J Haematol 2017; 178(2): 181–195. Dostupné z DOI: <http://dx.doi.org/10.1111/bjh.14632>.
32. Andrade D, Cervera R, Cohen H et al. 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. In: Erkan D, Lockshin MD (eds). Antiphospholipid Syndrome. Springer: Cham 2017: 317–338. ISBN 978–3319554402.
33. Marongiu F, Tosetto A, Palareti G. Special indications for vitamin K antagonists: a review. Intern Emerg Med 2012; 7(1): 21–25. Dostupné z DOI: <http://dx.doi.org/10.1007/s11739–011–0543–5>.
34. von Vajna E, Alam R, So TY. Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population. Cardiol Ther 2016; 5(1): 19–41. Dostupné z DOI: <http://dx.doi.org/10.1007/s40119–015–0054-y>.
35. Jacobson A. Is there a role for warfarin anymore? Hematology Am Soc Hematol Educ Program 2012; 2012: 541–546. Dostupné z DOI: <http://dx.doi.org/10.1182/asheducation-2012.1.541>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2017 Issue 12
Most read in this issue
- The current role of warfarin
- Citalopram and QT prolongation
- Drug induced tendon injury
- Unusual history of Wilson disease: a case report and review of the literature